Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Table 1 Antimicrobial susceptibility of S. pyogenes as classified by CLSI and EUCAST §

Antimicrobial agent^a(n° of strains)	CLSI susceptibility breakpoint (mg/L)	EUCAST susceptibility breakpoint (mg/L)	CLSI %S	EUCAST %S	Type of discrepancy^b
Penicillin (934)	≤0.12	≤0.25	99.9	100	-
Azithromycin (22.884)	≤0.5	≤0.25	91.7	91.2	-
Clindamycin (10.994)	≤0.25	≤0.5	96.6	96.7	-
Levofloxacin (26.775)	≤2	≤1	99.0	93.1	minor
Vancomycin (10.728)	≤1	≤2	100	100	-
Tetracycline (2.413)	≤2	≤1	83.9	83.7	-

§ CLSI [11] and EUCAST [13].
^AFor Erythromycin, Clarithromycin, Linezolid and Daptomycin CLSI and EUCAST suggested the same susceptibility breakpoints.
^b Discrepancy as defined in the materials and methods section.

ISSN: 1471-2334